Golden Swan Cadre Group

The FDA recently acknowledged Phase 3 trial data for Rexlemestrocel-L, an allogeneic cell therapy specifically for chronic discogenic low back pain. This treatment has shown a meaningful reduction in pain intensity for up to 12 months following a single administration.

In 2026, this therapy is a primary tool for "Opioid Cessation" programs. By treating the underlying inflammatory environment of the spinal discs, it allows patients who were previously dependent on long-term opioids to significantly reduce or entirely stop their medication use.